Shots:

• Medigene to receive $10M upfront- $1B as development- regulatory- and commercial milestones & royalties on sales of four products in multiple indications. Cytovant to get exclusive development & commercialization rights for Medigene’s TCR therapy for NY-ESO-1 and Dendritic cell (DC) vaccine targeting WT-1 & PRAME in Greater China- South Korea- and Japan
• Cytovant and Medigene have also entered into a research agreement for T-cell receptor (TCR) immunotherapies for two additional targets. Medigene to take care of generation and delivery of TCR constructs using TCR platform- with all R&D cost reimburse by Cytovant
• T cells are modified for adoptive T cell therapy with tested T cell receptors (TCR-Ts) which usually recognize and kill cancer or tumor cells 

Ref: Roivant | Image: Finsmes